Retrovir, Combivir(zidovudine)
/ Lamivudine / Zidovudine, Combivir, Lamivudine / Zidovudine, Retrovir, Trizivir, Zidovudine (zidovudine) is a small molecule pharmaceutical. Zidovudine was first approved as Retrovir on 1987-03-19. It is used to treat acquired immunodeficiency syndrome and HIV infections in the USA. It has been approved in Europe to treat HIV infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| infections | D007239 |
| urogenital diseases | D000091642 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Retrovir, Zidovudine (discontinued: Retrovir, Zidovudine)
CombinationsAbacavir sulfate, lamivudine zidovudine, Lamivudine zidovudine (discontinued: Combivir, Lamivudine zidovudine, Lamivudine, nevirapine zidovudine, Trizivir)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RETROVIR | ViiV Healthcare | N-019655 RX | 1987-03-19 | 1 products, RLD, RS |
| RETROVIR | ViiV Healthcare | N-019910 RX | 1989-09-28 | 1 products, RLD, RS |
| RETROVIR | ViiV Healthcare | N-019951 RX | 1990-02-02 | 1 products, RLD, RS |
Show 3 discontinued
Lamivudine
+
Nevirapine
+
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE | Micro Laboratories | N-205626 DISCN | 2018-08-13 | 1 products, RLD |
Hide discontinued
Lamivudine
+
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LAMIVUDINE AND ZIDOVUDINE | PharmaCare | N-022018 DISCN | 2017-03-17 | 1 products |
| COMBIVIR | ViiV Healthcare | N-020857 DISCN | 1997-09-26 | 1 products, RLD |
Hide discontinued
Abacavir sulfate
+
Lamivudine
+
Zidovudine
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIZIVIR | ViiV Healthcare | N-021205 DISCN | 2000-11-14 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abacavir sulfate, lamivudine and zidovudine | ANDA | 2013-12-17 |
| abacavir, lamivudine and zidovudine | ANDA | 2023-10-31 |
| azactam | New Drug Application | 2025-01-09 |
| aztreonam | ANDA | 2024-06-03 |
| cayston | New Drug Application | 2025-03-17 |
| combivir | New Drug Application | 2023-08-22 |
| compound w | C200263 | 2025-08-08 |
| compound w for kids one step strips | C200263 | 2024-10-25 |
| compound w one step pads | C200263 | 2024-10-25 |
| compound w one step plantar foot pads | C200263 | 2024-10-25 |
Show 15 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hiv infections | EFO_0000764 | D015658 | B20 |
| acquired immunodeficiency syndrome | EFO_0000765 | D000163 | B20 |
| hepatitis b | — | D006509 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J05: Antivirals for systemic use
— J05A: Direct acting antivirals
— J05AF: Nucleoside and nucleotide reverse transcriptase inhibitors
— J05AF01: Zidovudine
— J05AR: Antivirals for treatment of hiv infections, combinations
— J05AR01: Zidovudine and lamivudine
— J05AR04: Zidovudine, lamivudine and abacavir
— J05AR05: Zidovudine, lamivudine and nevirapine
Clinical
Clinical Trials
596 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Aids-related complex | D000386 | EFO_0007137 | B20 | — | 1 | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Zidovudine |
| INN | zidovudine |
| Description | Zidovudine is a pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase. It has a role as an antiviral drug, an antimetabolite and a HIV-1 reverse transcriptase inhibitor. It is a pyrimidine 2',3'-dideoxyribonucleoside and an azide. |
| Classification | Small molecule |
| Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O |
Identifiers
| PDB | — |
| CAS-ID | 30516-87-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL129 |
| ChEBI ID | 10110 |
| PubChem CID | 35370 |
| DrugBank | DB00495 |
| UNII ID | 4B9XT59T7S (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Azactam – Elan Corporation
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Zidovudine
+
Lamivudine
+
Abacavir
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Zidovudine
+
Lamivudine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Zidovudine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,408,264 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abacavir sulfate, lamivudine and zidovudine, Abacavir, lamivudine and zidovudine, Combivir, Direct rx, Lamivudine and zidovudine, Lamivudine zidovudine, Retrovir, Trizivir, Zidovudine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
30,930 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use